Company Overview
Company Type: Public Company
Website: angleplc.com
Number of Employees: 173
Ticker: AGL (AIM)
Year Founded: 1994


Business Description
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

Financial Information (Currency: CAD, in mm) 
Total Revenue
3.0
Market Capitalization
63.2
TEV/Total Revenue
11.1x
EBITDA
(40.0)
Total Enterprise Value
33.8
TEV/EBITDA
NM
EBIT
(41.8)
Cash & ST Invst.
37.1
P/Diluted EPS Before Extra
NM
Net Income
(37.3)
Total Debt
7.7
Price/Tang BV
1.3x
Capital Expenditure
(2.0)
Total Assets
67.3
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-05-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FH
Current FH+1
Current FY
Current FY+1
NTM
EPS Normalized
(0.07)
-
(0.13)
(0.12)
(0.12)
Revenue (mm)
3.01
-
5.02
15.49
10.26
EBITDA (mm)
-
-
(35.77)
(27.30)
(31.54)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
6.73x
TEV/EBITDA
NM
P/BV
1.61x

Non-Periodic Estimates

Recommendation
Buy (1.00)
Target Price
1.63
Potential Upside
571.26%


Key Professionals
Name
Title
Newland, Andrew David William
Founder, CEO & Executive Director
Griffiths, Ian Francis
CFO, Finance Director, Company Secretary & Executive Director
Cooke, Martin 
Director of Operations & Regulatory Affairs
Holder, Andrew John
Head of Investor Relations
Claxton, Nick 
Senior Vice President of Commercial Operations
Swansiger, Brett 
Chief Commercial Officer
Miller, Karen 
Chief Scientific Officer

Key Board Members
Name
Title
Groen, Jan 
Independent Non-Executive Chairman
Newland, Andrew David William
Founder, CEO & Executive Director
Griffiths, Ian Francis
CFO, Finance Director, Company Secretary & Executive Director
Selvey, Garth R.
Independent Non-Executive Director
Thompson, Juliet 
Non-Executive Director
Howlett, Brian 
Non-Executive & Senior Independent Director
Danila, Daniel Costin
Member of Scientific Advisory Board
Eid, Joseph E.
Non-Executive Director
Khoury, Joseph D.
Member of Scientific Advisory Board
Newland, Adrian 
Member of Scientific Advisory Board
Reuben, James M.
Member of Scientific Advisory Board
Shaw, Greg L.
Member of Scientific Advisory Board


Primary Industry Classification
Health Care Equipment


Primary Office Location
Surrey Research Park 10 Nugent Road | Guildford, Surrey | GU2 7AF | United Kingdom
Phone: 44 14 8334 3434   

Current and Pending Investors
Amati Global Investors Ltd., Covington Capital Corporation, Maven Capital Partners UK LLP, Rathbones Investment Management Limited, Unicorn Asset Management Ltd.

Prior Investors
Gateway VCT PLC, Hargreave Hale AIM VCT 2 plc, Keydata Investment Services Limited, Ortus VCT PLC, Thames Ventures VCT 1 plc (LSE:TV1)

Investment Arms
ANGLE Technology Ventures Limited (Prior)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.24
Market Cap (mm)
63.2
Open
 0.24
Shares Out. (mm)
260.5
Previous Close
 0.24
Float %
78.4%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.25/ 0.24
Diluted EPS Excl. Extra Items
(0.14)
52 wk High/Low
 1.11/ 0.18
P/Diluted EPS Before Extra
NM
Volume (mm)
0.30
Avg 3M Dly Vlm (mm)
0.83
Beta 5Y
0.39


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
AIM:AGL - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
ANGLE North America Inc.
ANGLE North America, Inc., a medical technology company, offers prenatal diagnostics products in Pennsylvania. The company's product identifies chromosomal abnormalities in the first trimester of pregnancy. It is useful in early diagnosis for chromosomal abnormalities associated with spina bifida, Down's, Turner, and Klinefelter syndromes. The company's technology, developed in laboratories in the United States and Europe, is also applicable to bone marrow transplant procedures used in cancer treatment. ANGLE North America, Inc. was formerly known as Parsortix, Inc. The company was founded in 2006 and is based in King Of Prussia, Pennsylvania.

United States and Canada
Biotechnology
0.00
-
-
ANGLE  Technology Ltd.
The company provides a range of specialist Consulting & Management services. ANGLE Technology Ltd. is a subsidiary of ANGLE Plc (AGL).

Europe
-
0.00
-
-
ANGLE Biosciences Inc.
ANGLE Biosciences Inc. is based in the United Kingdom. ANGLE Biosciences Inc. operates as a subsidiary of ANGLE Plc.

Europe
-
-
-
-
ANGLE Europe Limited
ANGLE Europe Limited develops medical diagnostics products. ANGLE Europe Limited was formerly known as Parsortix Limited and changed its name to ANGLE Europe Limited in August, 2015. The company was incorporated in 2006 and is based in Guildford, United Kingdom. ANGLE Europe Limited operates as a subsidiary of ANGLE Plc.

Europe
Health Care Equipment
-
-
-
Angle Ventures Limited

-
-
-
-
-
Innomatica Ltd.

-
-
-
-
-
Mogility Inc

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-14-2022
Jul-15-2022
Public Offering
Target
ANGLE plc (AIM:AGL)


23.89
Jun-24-2021
Jun-25-2021
Public Offering
Target
ANGLE plc (AIM:AGL)


27.82
Oct-27-2020
Oct-27-2020
Public Offering
Target
ANGLE plc (AIM:AGL)


25.62
Jun-25-2019
Jun-25-2019
Public Offering
Target
ANGLE plc (AIM:AGL)


22.89
Nov-05-2018
Nov-30-2018
Merger/Acquisition
Buyer
ANGLE North America Inc.
ANGLE plc (AIM:AGL)

0.61
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-03-2023
Product-Related Announcements
Angle plc Announces Publication of Study of Disseminated Tumour Cells (Dtcs) in Bone Marrow from Breast Cancer Patients Published in the International Journal of Molecular Sciences
Sep-07-2023
Earnings Calls
ANGLE plc, H1 2023 Earnings Call, Sep 07, 2023
Sep-04-2023
Product-Related Announcements
Angle plc Announces the Launch of Its Portrait™ Flex Ctc Assay
Jun-28-2023
Annual General Meeting
ANGLE plc, Annual General Meeting, Jun 28, 2023
Jun-05-2023
Executive/Board Changes - Other
ANGLE plc Announces Senior Management Appointments

Competitors
Agena Bioscience, Inc., ApoCell, Inc., Atossa Therapeutics, Inc. (NasdaqCM:ATOS), Biocept, Inc. (NasdaqCM:BIOC), Biodesix, Inc. (NasdaqGM:BDSX), BioFluidica, Inc., Biolidics Limited (Catalist:8YY), Cancer Genetics, Inc. (Acquired), Celsee, Inc. (Acquired), Circulogene Theranostics, Inc., DiaCarta, Inc., Epic Sciences, Inc., Fluxion Biosciences, Inc., Foundation Medicine, Inc., Genomic Health, Inc., GILUPI GmbH, GRAIL, LLC, Guardant Health, Inc. (NasdaqGS:GH), Illumina, Inc. (NasdaqGS:ILMN), Inivata Limited, Invitae Corporation (NYSE:NVTA), LungLife AI, Inc. (AIM:LLAI), Menarini Silicon Biosystems, Inc., Natera, Inc. (NasdaqGS:NTRA), NeoGenomics, Inc. (NasdaqCM:NEO), OncoDNA SA, QIAGEN Hannover GmbH (Acquired), Qiagen N.V. (NYSE:QGEN), Rarecells Diagnostics SAS, Roche Holding AG (SWX:ROG), ScreenCell SA, Sysmex Corporation (TSE:6869), Tempus Labs, Inc., Thermo Fisher Scientific Inc. (NYSE:TMO), U.S. Caris MPI, Inc.

M&A Advisors
Cavendish Securities Plc, finnCap Ltd, Harbottle & Lewis LLP


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
M&A Advisors
Cavendish Securities Plc, finnCap Ltd, Harbottle & Lewis LLP
Public Offering Advisors
Caruso Law Group, LLC, Cavendish Securities Plc, Eversheds Sutherland, finnCap Ltd, Joh. Berenberg, Gossler & Co. KG, London Branch, Pinsent Masons


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 15, 2023 12:17 AM
AGL
ANGLE plc (AGL.LON) - Medical Devices Product Pipeline Summary
Reports
137
Jefferies LLC
Codrington-Bartlett, Lucy-Emma Mary Sarah
Sep 13, 2023 05:06 PM
AGL
Strategy Defined; Focus on Commercial Execution; PT +15%
EPS Estimates*
12
GlobalData

Sep 13, 2023 03:14 AM
AGL
ANGLE Plc (AGL.LON) - Financial Analysis Review
Reports
283
Trinity Delta Research Limited
Gregorek, Lala Victoria
Sep 07, 2023 12:36 AM
AGL
Trinity Delta Lighthouse: ANGLE
Notes
2
Jefferies LLC
Codrington-Bartlett, Lucy-Emma Mary Sarah
Sep 07, 2023 12:24 AM
AGL
Early Signs of Progress; Continued Execution in 2H Key to Rebuilding Confidence
Notes
8
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Aug 31, 2023 06:00 PM
AGL
Is Angle PLC In Need of A Cure?
Ratings Change*
12
GlobalData

Aug 29, 2023 01:50 AM
AGL
ANGLE Plc (AGL.LON) - Medical Equipment - Deals and Alliances Profile
Reports
56
Jefferies LLC
Codrington-Bartlett, Lucy-Emma Mary Sarah
Jun 22, 2023 05:20 AM
AGL
Tweaking Estimates Post-2022 Results
EPS Estimates*
5
GlobalData

Jun 12, 2023 04:20 AM
AGL
ANGLE Plc (AGL.LON) - Financial Analysis Review
Reports
354
GlobalData

Jun 09, 2023 07:55 AM
AGL
ANGLE plc (AGL.LON) - Medical Devices Product Pipeline Summary
Reports
137


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Conifer Management, LLC

19,979,790

7.67

4.8

Jun-01-2023


Global Frontier Investments, LLC

13,868,946

5.32

3.4

Jun-01-2023


Keane, Dermot 

12,777,088

4.91

3.1

Jun-01-2023


HBOS Investment Fund Managers Limited

9,546,081

3.66

2.3

Jun-01-2023


A J Bell Holdings Limited, Asset Management Arm

9,041,595

3.47

2.2

Jun-01-2023


Barclays Bank PLC, Wealth and Investment Management Division

8,251,233

3.17

2.0

Jun-01-2023


Baillie Gifford & Co.

8,051,990

3.09

2.0

Jun-23-2023


Chelverton Asset Management Limited

7,500,000

2.88

1.8

Jun-01-2023


Newland, Andrew David William

7,304,686

2.80

1.8

Jun-01-2023


Polar Capital Holdings Plc

6,844,158

2.63

1.7

Jun-01-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
A J Bell Holdings Limited, Asset Management Arm
9,041,595
2,919,937
HBOS Investment Fund Managers Limited
9,546,081
2,234,851
Barclays Bank PLC,  Securities Investments
2,847,926
2,228,318
Barclays Bank PLC, Wealth and Investment Management Division
8,251,233
1,985,240
EFG Private Bank SA, Asset Management Arm
3,486,153
1,822,648

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Global Frontier Investments, LLC
13,868,946
(13,868,946)
Baillie Gifford & Co.
8,051,990
(7,245,077)
Fidelity International Ltd
2,010,324
(6,308,062)
Aegon Asset Management UK Plc
0
(5,287,903)
Morgan Stanley Investment Management Inc.
0
(4,024,584)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-14
LONDON BROKER RATINGS: JPMorgan ups Rio Tinto; Redburn likes Carnival
Alliance News
Sep-07
AIM WINNERS & LOSERS: CVS plunges on CMA vet probe; Angle ascends
Alliance News


Company Coverage
This company is not on any Coverage List.

Products
EMT IF Assay (Future), HyCEAD Multiplex Analysis System, Management Services, Mentoring Services, Parsortix Instruments and Cassettes, Parsortix PC1 Clinical System (Future), Parsortix System, Research and Development Services, Specialised Advisory and Direct Support Services, Support and Maintenance Services, Technology Consultancy Services


Upcoming Events
Date/Time
Type
Apr-23-2024
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-03-2023
-
ANGLE plc (AIM:AGL)
RNS
Non Regulatory Announcement
17 KB
Sep-29-2023
-
ANGLE plc (AIM:AGL)
RNS
Non Regulatory Announcement
17 KB
Sep-07-2023
-
ANGLE plc (AIM:AGL)
RNS
Interim Results
265 KB
Sep-04-2023
-
ANGLE plc (AIM:AGL)
RNS
Non Regulatory Announcement
17 KB
Aug-15-2023
-
ANGLE plc (AIM:AGL)
RNS
Notice of Results
14 KB
Jun-28-2023
Dec-31-2022
ANGLE plc (AIM:AGL)
Company Website
Annual Report
5 MB
Jun-05-2023
-
ANGLE plc (AIM:AGL)
RNS
Non Regulatory Announcement
22 KB
May-25-2023
-
ANGLE plc (AIM:AGL)
RNS
Re Agreement
24 KB
May-22-2023
-
ANGLE plc (AIM:AGL)
RNS
Directorate Change
21 KB
Apr-21-2023
-
ANGLE plc (AIM:AGL)
RNS
Non Regulatory Announcement
20 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Newland, Andrew David William (Founder, CEO & Executive Director)
Feb-09-2023
Ordinary Shares
125,000
59,731
Open Market Acquisition
1.74
Exchange Announcement
Griffiths, Ian Francis (CFO, Finance Director, Company Secretary & Executive Director)
Feb-09-2023
Ordinary Shares
67,500
32,934
Open Market Acquisition
5.61
Exchange Announcement
-
Feb-09-2023
Ordinary Shares
37,500
18,387
Open Market Acquisition
-
Exchange Announcement
-
Feb-09-2023
Ordinary Shares
30,000
14,547
Open Market Acquisition
-
Exchange Announcement
Griffiths, Ian Francis (CFO, Finance Director, Company Secretary & Executive Director)
Feb-09-2023
Ordinary Shares
(37,500)
(18,231)
Open Market Disposition
(2.87)
Exchange Announcement
Newland, Andrew David William (Founder, CEO & Executive Director)
Jul-19-2022
Ordinary Shares
125,000
164,444
Other Acquisition
1.77
Exchange Announcement
Griffiths, Ian Francis (CFO, Finance Director, Company Secretary & Executive Director)
Jul-19-2022
Ordinary Shares
37,500
49,333
Other Acquisition
3.12
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Groen, Jan 
Independent Non-Executive Chairman
44 14 8334 3434
-
jan.groen@novigenix.com
Newland, Andrew David William
Founder, CEO & Executive Director
+44 (0) 1483 343434
-

Griffiths, Ian Francis
CFO, Finance Director, Company Secretary & Executive Director
+44 (0) 1483 343434
-

Selvey, Garth R.
Independent Non-Executive Director
44 14 8334 3434
-

Thompson, Juliet 
Non-Executive Director
44 20 7776 1204
44 78 8078 8391

Howlett, Brian 
Non-Executive & Senior Independent Director
44 14 8334 3434
-

Danila, Daniel Costin
Member of Scientific Advisory Board
44 14 8334 3434
-
-
Eid, Joseph E.
Non-Executive Director
44 14 8334 3434
-

Khoury, Joseph D.
Member of Scientific Advisory Board
44 14 8334 3434
-
-
Newland, Adrian 
Member of Scientific Advisory Board
44 14 8334 3434
-

Reuben, James M.
Member of Scientific Advisory Board
44 14 8334 3434
-

Shaw, Greg L.
Member of Scientific Advisory Board
44 14 8334 3434
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Newland, Andrew David William
Founder, CEO & Executive Director
+44 (0) 1483 343434
-

Griffiths, Ian Francis
CFO, Finance Director, Company Secretary & Executive Director
+44 (0) 1483 343434
-

Cooke, Martin 
Director of Operations & Regulatory Affairs
44 14 8334 3434
-

Holder, Andrew John
Head of Investor Relations
(617) 292-8200
-

Claxton, Nick 
Senior Vice President of Commercial Operations
44 14 8334 3434
-

Swansiger, Brett 
Chief Commercial Officer
44 14 8334 3434
-

Miller, Karen 
Chief Scientific Officer
44 14 8334 3434
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
